Ivaltinostat is under clinical development by CrystalGenomics and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Ivaltinostat’s likelihood of approval (LoA) and phase transition for Pancreatic Cancer took place on 12 Apr 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Ivaltinostat Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Ivaltinostat is under development for the treatment of metastatic pancreatic ductal adenocarcinoma, myelodysplastic syndrome, acute myeloid leukemia, hepatocellular carcinoma, idiopathic pulmonary fibrosis (IPF), alport syndrome, nonalcoholic steatohepatitis, chronic kidney disease and coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It is administered through intravenous and oral route. It is a small molecule acts by targeting HDAC enzyme. It is developed based on SPS technology, SCP technology and SDF technology.
CrystalGenomics is a biopharmaceutical company that discovers and develops structural chemoproteiomics-based drugs. The company’s pipeline products include CG-650 used for the treatment of acute chronic pain; CG-651, targeting neuropathic pain; CG-598 against inflammatory bowel disease; CG-549 used for the treatment of infectious diseases; CG-745 investigating for the traetment of pancreatic cancer, myelodysplastic syndrome and acute myeloid leukemia; CG-806, against blood cancer and CG-750 for treating fibrosis. CrystalGenomics uses its proprietary technologies to determine the structure of proteins, generate lead compounds; and optimize novel leads to drug candidate compounds. The company also provides soluble, active and homogeneous forms of disease related proteins. CrystalGenomics is headquartered in Seongnam, South Korea.
Quick View Ivaltinostat LOA Data
|Highest Development Stage|